Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 3, 2003, Pages 639-649

  Critchley, Ian A ^a   Draghi, Deborah C ^a   Sahm, Daniel F ^a   Thornsberry, Clyde ^b   Jones, Mark E ^c   Karlowsky, James A ^a  

^a Focus Technologies Incorporated   (United States)

^b Focus Technologies   (United States)

^c Focus Technologies   (Netherlands)

Author keywords

Daptomycin; Gram positive pathogens; Multidrug resistant

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG CLASSIFICATION; ENTEROCOCCUS FAECIUM; EUROPE; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; ITALY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NETHERLANDS; NONHUMAN; PENICILLIN RESISTANCE; PORTUGAL; PREVALENCE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

CROSS INFECTION; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; GRAM-POSITIVE BACTERIA; HOSPITALS; HUMANS;

EID: 0037340692     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg130     Document Type: Article

References (38)

1. McGowan, J. E., Jr (2001). Increasing threat of Gram-positive bacterial infections in the intensive care setting. Critical Care Medicine 29, Suppl. 4, N67-9.
2. Bhavnani, S. M. & Ballow, C. H. (2000). New agents for Gram-positive bacteria. Current Opinions in Microbiology 3, 528-34.
3. Tally, F. P. & DeBruin, M. F. (2000). Development of daptomycin for Gram-positive infections. Journal of Antimicrobial Chemotherapy 46, 523-6.
4. Thorne, G. M. & Alder, J. (2002). Daptomycin: a novel lipopeptide antibiotic. Clinical Microbiology Newsletter 24, 33-40.
5. Alborn, W. E., Jr, Allen, N. E. & Preston, D. A. (1991). Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 35, 2282-7.
6. Rybak, M. J., Hershberger, E., Moldovan, T. & Cruz, R. G. (2000). In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrobial Agents and Chemotherapy 44, 1062-6.
7. Snydman, D. R., Jacobus, N. V., McDermott, L. A., Lonks, J. R. & Boyce, J. M. (2000). Comparative in vitro activities of daptomycin and vancomycin against Gram-positive pathogens. Antimicrobial Agents and Chemotherapy 44, 3447-50.
8. Barry, A. L., Fuchs, P. C. & Brown, S. D. (2001). In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrobial Agents and Chemotherapy 45, 1919-22.
9. King, A. & Phillips, I. (2001). The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. Journal of Antimicrobial Chemotherapy 48, 219-23.
10. Dutka-Malen, S., Evers, S. & Courvalin, P. (1995). Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. Journal of Clinical Microbiology 33, 24-7.
11. National Committee for Clinical Laboratory Standards. (2000). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Fifth Edition: Approved Standard M7-A5. NCCLS, Wayne, PA, USA.
12. National Committee on Clinical Laboratory Standards. (2002). Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement M100-S12. NCCLS, Wayne, PA, USA.
13. Stephenson, J. (2001). Researchers describe latest strategies to combat antibiotic-resistant microbes. Journal of the American Medical Association 285, 2317-8.
14. Eliopoulos, G. M., Willey, S., Reiszner, E., Spitzer, P. G., Caputo, G. & Moellering, R. C., Jr (1986). In vitro and in vivo activity of LY 146032, a new cyclic lipopepticle antibiotic. Antimicrobial Agents and Chemotherapy 30, 532-5.
15. Fass, R. J. & Helsel, V. L. (1986). In vitro activity of LY146032 against staphylococci, streptococci, and enterococci. Antimicrobial Agents and Chemotherapy 30, 781-4.
16. Verbist, L. (1987). In vitro activity of LY146032, a new lipopeptide antibiotic, against Gram-positive cocci. Antimicrobial Agents and Chemotherapy 31, 340-2.
17. Hodinka, R. L., Jack-Wait, K., Wannamaker, N., Walden, T. P. & Gilligan, P. H. (1987). Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial. European Journal of Clinical Microbiology 6, 100-3.
18. Ehlert, F. & Neu, H. C. (1987). In vitro activity of LY146032 (daptomycin), a new peptolide. European Journal of Clinical Microbiology 6, 84-90.
19. Jones, R. N. & Barry, A. L. (1987). Antimicrobial activity and spectrum of activity of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrobial Agents and Chemotherapy 31, 625-9.
20. 2+ and albumin on these drugs. Antimicrobial Agents and Chemotherapy 35, 1710-6.
21. Fuchs, P. C., Barry, A. L. & Brown, S. D. (2000). Daptomycin susceptibility tests: interpretative criteria, quality control, and effect of calcium on in vitro tests. Diagnostic Microbiology and Infectious Disease 38, 51-8.
22. Jones, R. N. (1989). Effects of reduced cation supplement recommendations (National Committee for Clinical Laboratory Standards) on daptomycin antistaphylococcal activity. Antimicrobial Agents and Chemotherapy 33, 1652-3.
23. Fuchs, P. C., Barry, A. C. & Brown, S. D. (2001). Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media. Journal of Antimicrobial Chemotherapy 48, 557-61.
24. Wise, R., Andrews, J. M. & Ashby, J. P. (2001). Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. Journal of Antimicrobial Chemotherapy 48, 563-7.
25. Snell, J. J. & Brown, D. F. (2001). External quality assessment of antimicrobial susceptibility testing in Europe. Journal of Antimicrobial Chemotherapy 47, 801-10.
26. Gruneberg, R. N. & Hryniewicz, W. (1998). Clinical relevance of a European collaborative study on comparative susceptibility of Gram-positive clinical isolates to teicoplanin and vancomycin. International Journal of Antimicrobial Agents 10, 271-7.
27. Felmingham, D., Brown, D. F. & Soussy, C. J. (1998). European glycopeptide susceptibility survey of Gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group. Diagnostic Microbiology and Infectious Disease 31, 563-71.
28. Schouten, M. A., Hoogkamp-Korstanje, J. A., Meiss, J. F. & Voss, A. European VRE Study Group. (2000). Prevalence of vancomycin-resistant enterococci in Europe. European Journal of Clinical Microbiology and Infectious Diseases 19, 816-22.
29. Sahm, D. F., Jones, M. E., Hickey, M. L., Diakun, D. R., Mani, S. V. & Thornsberry, C. (2000). Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolates in Asia and Europe, 1997-1998. Journal of Antimicrobial Chemotherapy 45, 457-66.
30. Sahm, D. F., Karlowsky, J. A., Kelly, L. J., Critchley, I. A., Jones, M. E., Thornsberry, C. et al. (2001). Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrobial Agents and Chemotherapy 45, 1037-42.
31. Whitney, C. G., Farley, M. M., Hadler, J., Harrison, L. H., Lexau, C., Reingold, A. et al. (2000). Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. New England Journal of Medicine 343, 1917-24.
32. Bronzwaer, S. L., Bucholz, U. & Kool, J. L. (2001). International surveillance of antibiotic resistance in Europe: now we also need to monitor antibiotic usage. European Surveillance 6, 1-2.
33. Livermore, D. M. (2000). Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? Journal of Antimicrobial Chemotherapy 46, 347-50.
34. Silverman, J. A., Oliver, N., Andrew, T. & Li, T. (2001). Resistance studies with daptomycin. Antimicrobial Agents and Chemotherapy 45, 1799-802.
35. Gonzales, R. D., Schreckenberger, P. C., Graham, M. B., Kelkar, S., DenBesten, K. & Quinn, J. P. (2001). Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357, 1179.
36. Tsiodras, S., Gold, H. S., Sakoulos, G., Eliopoulos, G. M., Wennersten, C., Venkataraman, L. et al. (2001). Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207-8.
37. Herrero, I. A., Issa, N. C. & Patel, R. (2002). Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. New England Journal of Medicine 346, 867-9.
38. Wilson, P., Andrews, J. A., Charlesworth, R., Walesby, R., Singer, M., Farrell, D. J. et al. (2003). Linezolid resistance in clinical isolates of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 51, 186-8.